The requirement for CD28 in PD-1 mediated inhibition of T cell activation (Hui et al., 2017; Kamphorst et al., 2017) also suggests eIF3-mediated control of TCR expression may affect PD-1 checkpoint blockade-based cancer immunotherapy (Jiang et al., 2019). The gene discussed is CD28; the disease is cancer.